Advanced Therapies Medicines
Cell and gene therapy
Free event |
|
Come and interact with regional scientific, industrial and clinical experts
|
|
|
The latest innovations on advanced therapy medicines (ATMs). The day focused on the intervention of experts discussing new targets in scientific research, clinical and industrial developments and associated regulations.
Don't miss the key moments of this day to discover and understand:
- THE challenges, trends et industrial dynamics particularly at the national level
- The latest major advances in search for new targets on
- Mesenchymal stromal cells
- Bio-impression
- Human pluripotent cells
- New strategies and applications clinics in oncologists
- The industrial processes of major accounts
- Key stages and challenges of the industrialization of MTIs
- Innovative machines and equipment
- Technological platforms in bioproduction
- Production process allogenic highly efficient
- Evaluate the genetic integrity of stem cells
- The issues and consequences legal for themarket access from MTIs
|
|
|
|
|
- 8.45: Welcome coffee
- 9.15: Opening – Introduction: national context and industrial dynamics
- Opening and introduction of the day
- Mr. Emmanuel Le Bouder, Innovation Director – Eurobiomed
- Bioproduction – Making France a European leader by 2030
- Mr. Emmanuel Dequier, Director of the Grand Défi Bioproduction, General Secretariat for Investment
- MTI - an accelerating ecosystem
- M. Olivier Revelant, Président & COO – Octopusyx Bioconsulting
- 10.00: The search for new targets: the latest major advances
- Modes of action of MSCs and therapeutic perspectives
- Pr. Louis Casteilla, Director STROMALab – Inserm, University of Toulouse
- Regenerative cell therapy of the bronchi using reprogrammed stem cells (iPS). Example of ciliary dyskinesia
- Pr. John De Vos, Head of the cellular and tissue engineering department and the Cellular Therapy Unit medical team – Inserm, Montpellier University Hospital, IRMB, University of Montpellier
- 3D bioprinting of skin: from theory to therapeutic application
- Dr. Jérémy Magalon, Assistant Professor Cellular Therapy Department – AP-HM, Conception Hospital
- 11.00: Coffee break
- 11.20: New clinical applications of MTIs
- Rapid adoption of Immune Effector Cells based therapies in real world conditions : the first commercial success for ATMPs
- Pr. Christian Chabannon, Head of Department, Head of the Cellular Therapy Center – Paoli Calmettes Institute
- Development of an innovative therapy drug CART-cells targeting IL-1RAP: from idea to phase I/IIa clinical trial
- Dr. Christophe Ferrand, Onco-hematological Laboratory Manager – Establishment Français du Sang Besançon
- TX200: CAR-Treg cell therapy for renal transplantation
- Dr. David Fenard, Directeur Cell Engineering – Sangamo Therapeutics
- 12.20: Lunch cocktail – networking
- 2:30 p.m.: The challenge of production processes for major accounts
- ATMP Manufacturing process : Keys steps & Challenges of Industrialization – Introduction to T2 Evolve (IMI)
- Ms. Hélène Nègre, CMC Project Leader – Servier
- From Process Development to Manufacturing of Cell Therapy : the important role of Equipment and Service Supplier like Sartorius
- M. Quentin Vicard, Manager External & Strategic Collaborations Cell Therapies – Sartorius
- 15.20 : Challenges in bioproduction: the innovative technologies of tomorrow
- The challenge of producing according to good manufacturing practices.
- Dr. Philippe Bourin, Expert Senior – Cell-Easy
- Genetic integrity of cells for therapeutic purposes
- Dr. Agnès Miermont, Responsable R&D – Stem Genomics
- 4:20 p.m.: Coffee break
- 16.40: Issues and consequences of the regulatory and legal framework for MTIs
- Ms Aurélie Mahalatchimy, Researcher – CNRS, Aix-Marseille University
|
|
|
IN PARTNERSHIP WITH
WITH THE SUPPORT OF THE SCIENTIFIC COMMITTEE
 
  
 
 
|
|
Information and registration:
Nicolas Sainte-Foie
nicolas.saintefoie@eurobiomed.org
